Ascom Holding AG
14.5.2019 14:02:50 CEST | Globenewswire | Press release
Ascom calls listing “yet another exciting step forward” for its flagship healthcare mobile device
BAAR, Switzerland, May 14, 2019 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), the global solutions provider focused on healthcare ICT and mobile workflow solutions, has announced that the Ascom Myco 3 smartphone has been listed on the Target Platform for the Epic Rover healthcare application. The app gives clinical users of Epic’s Electronic Health Record access to tools for clinical review, medication administration, specimen collection, and other clinical documentation workflows right from their mobile devices.
Part of the Ascom Healthcare Platform, the Ascom Myco 3 smartphone is available in cellular and Wi-Fi versions. Running on the Android 8.1 OS, the device features a HD 5” touchscreen, an integrated enterprise-grade barcode scanner, NFC functionality and a true hot-swappable battery. It works together with Ascom and third-party software and apps to put context-rich information from multiple sources into the hands of highly mobile clinicians. Designed for clinical and other demanding environments, the Ascom Myco 3 combines a robust yet ergonomic form with advanced integration capabilities and enterprise-grade security features.
For Ascom Chief Sales and Marketing Officer Francis Schmeer, the listing is “yet another exciting step forward for the Ascom Myco 3 smartphone.” The device works with apps such as Rover to connect clinicians to patient data, colleagues and IT systems—helping to streamline workflows, boost productivity and ultimately contribute to enhanced patient satisfaction and outcomes.
Schmeer also points to the app’s interoperability with the Ascom Myco 3 embedded barcode scanner as an example of how the smartphone enables mobile functionality for clinicians. “The Ascom Myco 3 barcode scanner lets clinicians securely identify patients, medications and colleagues at the point of care and while on the go. It’s a clear illustration of how the smartphone benefits busy clinicians, enabling smooth access to key data, and the ability to communicate and coordinate with colleagues, systems and patients.”
Epic and Rover are registered trademarks of Epic Systems Corporation.
Android is a trademark of Google LLC.
About Ascom
Ascom is a global solutions provider focused on healthcare ICT and mobile workflow solutions. The vision of Ascom is to close digital information gaps allowing for the best possible decisions – anytime and anywhere. Ascom’s mission is to provide mission-critical, real-time solutions for highly mobile, ad hoc, and time-sensitive environments. Ascom uses its unique product and solutions portfolio and software architecture capabilities to devise integration and mobilization solutions that provide truly smooth, complete, and efficient workflows for healthcare as well as for industry and retail sectors.
Ascom is headquartered in Baar (Switzerland), has operating businesses in 18 countries and employs around 1,300 people worldwide. Ascom registered shares (ASCN) are listed on the SIX Swiss Exchange in Zurich.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN:CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
